Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes. 

Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.

South Korean ministries release comprehensive broad steps under new government aimed at accelerating investment to deal with infectious diseases and supporting regulatory innovation, including speeding up processes, to match global standards, support new technologies and improve access.

Private sector efforts to lower cost sharing for insulin continue but patient advocates and lawmakers still believe legislation is needed to tackle the issue in a comprehensive way.